Billionaire Investor Stanley Druckenmiller’s Top 5 Picks: Worth Buying Today?

Stanley Druckenmiller doesn't bash consensus. The Duquesne Family Office's latest 13F reveals a top-five agelong publication that skips the mega-cap tech herd astir entirely: a Mexican discount grocer, 2 biotech names connected wildly antithetic trajectories, the 1 semiconductor banal cipher tin ignore, and an Argentine lipid shaper sitting connected a shale reserve astir to unlock its archetypal export pipeline. Miss this representation and you're paying retail for what helium already owns.

1. BBB Foods (TBBB): The Mexican Discounter Nobody's Talking About

The astonishment anchor of the portfolio is BBB Foods (NYSE:TBBB), a $4.84 cardinal hard-discount grocer moving the Tiendas 3B banner crossed Mexico. This is simply a countercyclical stake dressed up arsenic a maturation story: the weaker the Mexican user gets, the faster private-label discount stores seizure wallet share. Druckenmiller is buying the symptom trade.

The Q1 2026 numbers explicate the conviction. Revenue grew 33.44% year-over-year to astir Ps.22.86 billion, same-store income precocious 16.0%, and the store basal expanded to 3,469 units aft 123 nett openings successful the quarter. CEO K. Anthony Hatoum framed it plainly: "Despite a brushed user situation successful Mexico, we achieved same-store income (SSS) maturation of 16.0% successful 1Q26, underscoring the spot of our worth proposition and expanding lawsuit loyalty."

The exemplary puts a base-case one-year people of $50.82, oregon 26.89% upside, with analysts divided 75% bullish and zero bearish. The setup skews constructive. And the 2nd sanction connected Druckenmiller's database is simply a precise antithetic benignant of asymmetric bet, wherever the motorboat curve is already vertical.

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Taiwan Semiconductor Manufacturing didn't marque the cut. Grab the names FREE today.

2. Insmed (INSM): The BRINSUPRI Breakout

Insmed (NASDAQ:INSM) is simply a rare-disease pharma whose recently launched bronchiectasis cause BRINSUPRI has turned into 1 of the fastest specialty-drug ramps of the decade. Druckenmiller is positioned for what happens erstwhile a first-in-class therapy meets a captive prescriber basal with fundamentally nary competition.